A design for phase II testing of anticancer agents within a phase III clinical trial

Daniel J. Schaid, James N. Ingle, Sam Wieand, David L. Ahmann

Research output: Contribution to journalArticlepeer-review

30 Scopus citations

Abstract

A design for testing new anticancer agents is proposed such that the initial testing of new agents (phase II trials) is included within the framework of a comparative clinical trial (phase III). Randomization between phase II trials and the treatment groups of the phase III trial enforces consistency of patient selection and evaluation of response criteria. Patients who progress on the phase II trials of the new agents are randomized to one of the treatments of the phase III trial. Design issues, such as sample size and power, and analysis of the proposed design, are discussed. Advantages and disadvantages of the design are illustrated by sample size calculations for a current clinical trial in advanced breast cancer.

Original languageEnglish (US)
Pages (from-to)107-118
Number of pages12
JournalControlled Clinical Trials
Volume9
Issue number2
DOIs
StatePublished - Jun 1988

Keywords

  • Randomized design
  • phase II Anticancer agents
  • phase III survival comparison

ASJC Scopus subject areas

  • Pharmacology

Fingerprint Dive into the research topics of 'A design for phase II testing of anticancer agents within a phase III clinical trial'. Together they form a unique fingerprint.

Cite this